Form 8-K - Current report:
SEC Accession No. 0001193125-23-274068
Filing Date
2023-11-09
Accepted
2023-11-09 07:39:59
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d243880d8k.htm   iXBRL 8-K 24662
2 EX-99.1 d243880dex991.htm EX-99.1 108447
6 GRAPHIC g243880g1109093641013.jpg GRAPHIC 6221
  Complete submission text file 0001193125-23-274068.txt   278182

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA wve-20231109.xsd EX-101.SCH 2874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE wve-20231109_lab.xml EX-101.LAB 17926
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE wve-20231109_pre.xml EX-101.PRE 11254
8 EXTRACTED XBRL INSTANCE DOCUMENT d243880d8k_htm.xml XML 3326
Mailing Address 733 CONCORD AVENUE CAMBRIDGE MA 02138
Business Address 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE U0 018936 617-949-2900
Wave Life Sciences Ltd. (Filer) CIK: 0001631574 (see all company filings)

EIN.: 000000000 | State of Incorp.: U0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37627 | Film No.: 231390096
SIC: 2834 Pharmaceutical Preparations